Menu Search
Equities

Gossamer Bio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4GB:DUS

Gossamer Bio Inc

Actions
  • Price (EUR)1.94
  • Today's Change-0.095 / -4.66%
  • Shares traded--
  • 1 Year change+86.29%
  • Beta1.9474
Data delayed at least 15 minutes, as of Feb 06 2026 18:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

  • Revenue in USD (TTM)44.05m
  • Net income in USD-156.16m
  • Incorporated2015
  • Employees144.00
  • Location
    Gossamer Bio Inc3115 MERRYFIELD ROW, SUITE 120SAN DIEGO 92121United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.gossamerbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.